【李學耘】論文著作目錄
編號出版年份論文引用名稱PMID作者序論文分類論文種類
12024Enhancing anti-cancer capacity: Novel class I/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways. Bioorg. Med. Chem..(109):117792-.
Lee, H. Y., Hsu, M. J., Chang, H. H., Chang, W. C., Huang, W. C., Cho, E. C.		388971391Original PaperSCI
22024Discovery of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors using an artificial intelligence model and their effects on tau and tubulin dynamics. Biomed. Pharmacother..(181):117688-.
Chen, J. H., Tu, H. J., Lin, T. E., Peng, Z. X., Wu, Y. W., Yen, S. C., Sung, T. Y., Hsieh, J. H., Lee, H. Y., Pan, S. L., HuangFu, W. C.*, Hsu, K. C.*		　6Original PaperSCI
32023In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer. J. Enzyme Inhib. Med. Chem..(38):2166039-.
Chang, C. D., Chao, M. W., Lee, H. Y., Liu, Y. T., Tu, H. J., Lien, S. T., Lin, T. E., Sung, T. Y., Yen, S. C., Huang, S. H., Hsu, K. C., Pan, S. L.		　3Original PaperSCI
42023CuI-mediated synthesis of 1-aryl-5,6,7-trimethoxybenzimidazoles as potent antitubulin agents. RSC Adv..(13):13169-13176.
Peng, C. M., Wang, S. W., Hwang, Y. L., Sun, W. C., Chiu, L. P., Liu, Y. T., Lai, Y. W., Lee, H. Y.		　6&通訊Original PaperSCI
52023Definition of fatty acid transport protein-2 (FATP2) structure facilitates identification of small molecule inhibitors for the treatment of diabetic complications. Int. J. Biol. Macromol..(244):125328-.
Kumar, M., Gaivin, R. J., Khan, S., Fedorov, Y., Adams, D. J., Zhao, W., Lee, H. Y., Dai, X., Dealwis, C. G., Schelling, J. R.*		373079676Original PaperSCI
620236-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers. Eur. J. Med. Chem..(258):115505-.
Narwanti, I., Yu, Z. Y., Sethy, B., Lai, M. J., Lee, H. Y., Olena, P., Lee, S. B., Liou, J. P.		　5Original PaperSCI
72023Synthesis and evaluation of potent (iso)ellipticine-based inhibitors of MYLK4 accessed via expeditious synthesis from isoquinolin-5-ol. RSC Adv..(13):31595-31601.
Lee, S., Chao, M. W., Wu, Y. W., Hsu, C. M., Lin, T. E., Hsu, K. C., Pan, S. L., Lee, H. Y.*		　6&通訊Original PaperSCI
82022A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation. Chem. Biol. Interact..(352):109778-.
Lee, H. Y., Tang, D. W., Liu, C. Y., Cho, E. C.*		　1Original PaperSCI
92022Method of modulating ribonucleotide reductase. US20220249457.
Dealwis, C., Lee, H. Y., Viswanathan, R., Huff, S.		　2PatentOther
102021Ring size changes in the development of class I HDAC inhibitors. J. Enzyme Inhib. Med. Chem..(36):1387-1401.
Cho, E. C., Liu, C. Y., Tang, D. W., Lee, H. Y.*		341674194&通訊Original PaperSCI
112021Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. Bioorg. Med. Chem..(50):116454-.
Lee, S., Wang, S. W., Yu, C. L., Tai, H. C., Yen, J. Y., Tuan, Y. L., Wang, H. H., Liu, Y. T., Chen, S. S.*, Lee, H. Y.*		　6&通訊Original PaperSCI
122021Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases. Eur. J. Med. Chem..(227):113904-.
Lee, S. B., Chang, T. Y., Lee, N. Z., Yu, Z. Y., Liu, C. Y., Lee, H. Y.*		　6&通訊Original PaperSCI
132021Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors. J. Enzyme Inhib. Med. Chem..(37):226-235.
Lin, T. E., Sung, L. C., Chao, M. W., Li, M., Zheng, J. H., Sung T. Y., Hsieh, J. H., Yang, C. R., Lee, H. Y., Cho, E. C.*, Hsu, K. C.*		　6Original PaperSCI
142020Synthesis and biological evaluation of 2-quinolineacrylamides. Bioorg. Med. Chem..(28):115250-.
Wang, S. W., Lin, M. H., Hsu, F. C., Chen, M. C., Liou, J. P., Liu, Y. T., Chen, S. S., Lee, H. Y.*		319245046&通訊Original PaperSCI
152020HDAC inhibitor protects chronic cerebral hypoperfusion and oxygen-glucose deprivation injuries via H3K14 and H4K5 acetylation-mediated BDNF expression. J. Cell. Mol. Med..(24):6966-6977.
Fang, Y. C., Chan, L., Liou, J. P., Tu, Y. K., Lai, M. J., Chen, C. I., Vidyanti, A. N., Lee, H. Y.*, Hu, C. J.*		323740846&通訊Original PaperSCI
162020Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms. J. Enzyme Inhib. Med. Chem..(36):74-84.
Mehndiratta, S., Chen, M. C., Chao,Y. H., Lee, C. H., Liou, J. P., Lai, M. J.*, Lee, H. Y.*		　6&通訊Original PaperSCI
172020Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. Eur. J. Med. Chem..(187):111915-.
Kaur, N., Fang, Y. C., Lee, H. Y., Singh, A., Nepali, K., Lin, M. H., Yeh, T. K., Lai, M. J., Chan, L., Tu, Y. K., Banerjee, S., Hu, C. J.*, Liou, J. P.*		318383293Original PaperSCI
182019Structure-guided design of anti-cancer ribonucleotide reductase inhibitors. J. Enzyme Inhib. Med. Chem..(34):438-450.
Misko, T. A., Liu, Y. T., Harris, M. E., Oleinick, N. L., Pink, J., Lee, H. Y.*, Dealwis, C. G.*		　6&通訊Original PaperSCI
192019Nitro-Group-Containing Drugs. J. Med. Chem..(6):2851-2893.
Nepali, K., Lee, H. Y., Liou, J. P.*		302954772Review PaperSCI
2020191-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase. Eur. J. Med. Chem..(162):612-630.
Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y.*, Liou, J. P.*		304768255Original PaperSCI
212018A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo. Front Pharmacol..(9):205-.
Wu, Y. W., Hsu, K. C., Lee, H. Y., Huang, T. C., Lin, T. E., Chen, Y. L.,Sung, T. Y., Liou, J. P., Hwang-Verslues, W. W., Pan, S. L., HuangFu, W. C.*		295935363Original PaperSCI
222018(N‑Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo. J. Med. Chem..(61):905-917.
Lee, H. Y., Nepali, K., Huang, F. I., Chang, C. Y., Lai, M. J., Li, Y. H., Huang, H.L., Yang, C. R.*, Liou, J. P.*		293042841Original PaperSCI
2320185-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer's disease phenotypes. J. Med. Chem..(61):7087-7102.
Lee, H. Y., Fan, S. J., Huang, F. I., Chao, H. Y., Hsu, K. C., Lin, T. E., Yeh, T. K., Lai, M. J., Li, Y. H., Huang, H. L., Yang, C. R.*, Liou, J. P.*		300286161Original PaperSCI
2420173-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity. Eur. J. Med. Chem..(125):1268-1278.
Lee, H. Y., Lee, J. F., Kumar, S., Wu, Y. W.;, HuangFu, W. C.		278865441Original PaperSCI
252017Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. Eur. J. Med. Chem..(127):115-127.
Nepali, K., Lee, H. Y., Lai, M. J., Ojha, R., Wu, T. Y., Wu, G. X.; Chen, M. C.*; Liou, J. P.		280383241Original PaperSCI
262017Total Synthesis of Two Glycosylated Stilbenes, Oxyresveratrol 2-O-β- d -Glucopyranoside and 2,3,5,4′-Tetrahydroxystilbene 2-O-β- d -Glucopyranoside. Journal of Natural Products.(80):1294-1301.
Kumar, S., Lee, H. Y., Liou, J. P.		284299372Original PaperSCI
272017Total synthesis of two glycosylated stilbenes, oxyresveratrol 2-O-β-D-glucopyranoside and 2,3,5,4’-tetrahydroxystilbene 2-O-β-D-glucopyranoside. J. Nat. Prod..(80):1294-1301.
Kumar, S., Lee, H. Y., Liou, J. P.		284299372Original PaperSCI
282016Total synthesis of denbinobin. J. Nat. Prod..(79):1170-1173.
Lee, H. Y., Kumar, S., Lin, T. C., Liou, J. P.		270105701Original PaperSCI
2920162-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase. Eur. J. Med. Chem..(122):92-101.
Lee, H. Y., Chang, C. Y., Su, C. J., Huang, H. L., Mehndiratta, S., Chao, Y. H.; Hsu, C. M.; Kumar, S.; Sung, T. Y.; Huang, Y. Z.; Li, Y. H.; Yang, C. R.*; Liou, J. P.		273444871Original PaperSCI
302016Development of Bioactive 1,4-Benzoquinone-Containing Derivatives. .
Lee HY		　1Conference PaperOther
3120162-(Phenylsulfonyl)quinoline N-Hydroxyacrylamides as Potent Anticancer Agents Inhibiting Histone Deacetylase. .
Chang HH, Lee HY		　其他&通訊Conference PaperOther
3220162-Aroylquinoline-5,8-diones as Potent Anticancer Agents Displaying Tubulin and Heat Shock Protein 90 (HSP90) Inhibition. .
Nepali K, Huang HL, Kuo FC, Lee CH, Kuo CC, Li YH, Chang JY, Liou JP, Lee HY		　其他&通訊Conference PaperOther
332015Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes. Bioorg. Med. Chem..(23):4230-4236.
Lee HY, Chang CY, Lai MJ, Chuang HY, Kuo CC, Chang CY, Chang JY, Liou JP		261600201Original PaperSCI
342015N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling. J. Med. Chem..(58):6549-6558.
Lai MJ, Lee HY, Chuang HY., Chang LH, Tsai AC, Chen MC, Huang HL, Wu YW, Teng CM, Pan SL, Liu YM, Mehndiratta S, Liou JP		262410321Original PaperSCI
352015Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells. Org. Biomol. Chem..(13):10226-10235.
Liu YM, Lee HY, Lai MJ, Pan SL, Huang HL, Kuo FC, Chen MC*, Liou JP*		263091222Original PaperSCI
3620152-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Org. Biomol. Chem..
Nepali K, Kumar S, Huang HL, Kuo FC, Lee CH, Kuo CC, Yeh TK, Li YH, Chang JY, Liou JP and Lee HY*		　其他&通訊Original PaperSCI
3720152-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Org. Biomol. Chem..(14):716-723.
Nepali K, Kumar S, Huang HL, Kuo FC, Lee CH, Kuo CC2, Yeh TK, Li YH, Chang JY, Liou JP, Lee HY*		26694589其他&通訊Original PaperSCI
3820151-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. Eur. J. Med. Chem..(89):320-330.
Liu, Y. M., Lee, H. Y., Chen, C. H., Lee, C. H., Wang, L. T., Pan, S. L., Lai, M. J., Yeh, T. K., Liou, J. P.		254622482Original PaperSCI
392015Denbinobin upregulates miR-146a expression and attenuates IL-1β-induced upregulation of ICAM-1 and VCAM-1 expressions in osteoarthritis fibroblast-like synoviocytes. J. Mol. Med. (Berl)..
Yang, C. R., Shih, K. S., Liou, J. P., Wu, Y. W., Hsieh, I. N., Lee, H. Y., Lin, T. C., Wang, J. H.		25052989其他Original PaperSCI
402015Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. Bioorg. Med. Chem..(22):4917-4923.
Mehndiratta, S., Chiang, Y. F., Lai, M. J., Lee, H. Y., Chen, M. C., Kuo, C. C., Chang, C. Y., Chang, J. Y., Liou, J. P.		250595034Original PaperSCI
412015Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity. Eur. J. Med. Chem..(85):468-479.
Mehndiratta, S., Hsieh, Y. L., Liu, Y. M., Wang, A. W., Lee, H. Y., Liang, L. Y., Kumar, S., Teng, C. M., Yang, C. R., Liou, J. P.		251138755Original PaperSCI
422014Azaindolylsulfonamides, with a More Selective Inhibitory Effect on Histone Deacetylase 6 Activity, Exhibit Antitumor Activity in Colorectal Cancer HCT116 Cells. Journal of Medicinal Chemistry.(57):4009-4022.
Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Liu YM, Liu JF, Yeh TK, Wang JC, Chang CY, Chang JY, Liou JP		247665601Original PaperSCI
432014Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry.(77):306-314.
Chang CY, Chuang HY, Lee HY, Yeh TK, Kuo CC, Chang CY, Chang JY, Liou JP		246575673Original PaperSCI
442014Tubulin inhibitors: a patent review. Expert Opinion on Therapeutic Patents.(24):69-88.
Liu YM, Chen HL, Lee HY, Liou JP		243137413Review PaperSCI
452014Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death & Disease.(5):e1166-.
Hsieh IN, Liou JP, Lee HY, Lai MJ, Li YH, Yang CR		247222913Original PaperSCI
462014A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget.(5):9838-9850.
Wang, C. Y., Liou, J. P, Tsai, A. C, Lai, M. J., Liu, Y. M., Lee, H. Y., Wang, J. C., Pan, S. L., Teng, C. M.		25226613其他Original PaperSCI
472014Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases. Org. Biomol. Chem..(12):8966-8976.
Lee, H. Y., Wang, L. T., Li, Y. H., Pan, S. L., Chen, Y. L, Teng, C. M., Liou, J. P.		252772501Original PaperSCI
482013Furanylazaindoles: Potent Anticancer Agents in Vitro and in Vivo. Journal of Medicinal Chemistry.(53):8008-8018.
Lee HY, Pan SL, Su MC, Liu YM, Kuo CC, Chang YT, Wu JS, Nien CY, Mehndiratta S, Chang CY, Wu SY, Lai MJ, Chang JY*, Liou JP*		241069821Original PaperSCI
4920131-Arylsulfonyl-5-(N-hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors. CHEMBIOCHEM.(14):1248-1254.
Lee HY, Yang CR, Lai MJ, Huang HL, Hsieh YL, Liu YM, Yeh TK. Li YH, Mehndiratta S, Teng CM, Liou JP*		237882541Original PaperSCI
502012Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo. PLoS ONE.(8):e43645-e43645.
Huang, H. L, Lee, H. Y., Tsai, A. C., Peng, C. Y., Lai, M. J., Wang, J. C., Pan, S. L., Teng, C. M., Liou, J. P.		229280101Original PaperSCI
512012Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-(N-hydroxyacrylamide) indoles as Potent Histone Deacetylase Inhibitors with Antitumor Activity in vivo. J. Med. Chem..(55):3777-3791.
Lai, M. J., Huang, H. L., Pan, S. L., Liu, Y. M., Peng, C. Y., Lee, H. Y., Yeh, T. K., Hung, P. H., Teng, C. M., Chen, S. H., Chuang, H. Y., Liou, J. P.		22439863其他Original PaperSCI
522012Application of Suzuki arylation, Sonogashira ethynylation and Rosenmund-von Braun cyanation in the exploration of substitution effects on the anticancer activity of 2-aroylquinolines. Org. Biomol. Chem.(10):9593-9600.
Lee, H. Y., Lee, L. W., Nien, C. Y., Kuo, C. C., Lin, P. Y., Chang, C. Y., Chang, J. Y., Liou, J. P.		231323251Original PaperSCI
5320112-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors. ChemMedChem.(6):450-456.
Chuang, H. Y., Chang, J. Y., Lai, M. J., Kuo, C. C., Lee, H. Y., Hsieh, H. P., Chen, Y. J., Chen, L. T., Pan, W. Y., Liou, J. P.		213608195Original PaperSCI
542011Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Org. Biomol. Chem..(9):3154-3157.
Lee, H. Y., Chang, J. Y., Chang, L. Y., Lai, W. Y., Lai, M. J., Shih, K. H., Kuo, C. C., Hsieh, H. P., Chang, C. Y., Liou, J. P.		214160701Original PaperSCI
552011Synthesis and Biological Evaluation of 4-Aroyl-6,7,8-Trimethoxyquinolines as a Novel Class of Anticancer Agents. Molecules.(16):2274-2284.
Hsieh, C. C., Lee, H. Y., Nien, C. Y., Kuo, C. C., Chang, C. Y., Chang, J. Y., Liou, J. P.		213836642Original PaperSCI
562011Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents. Eur. J. Med. Chem..(46):3623-3629.
Lai, M. J., Chang, J. Y., Lee, H. Y., Kuo, C. C., Lin, M. H., Hsieh, H. P., Chang, C. Y., Wu, J. S., Wu, S. Y., Shey, K. S., Liou, J. P.		216417003Original PaperSCI
5720115-Amino-2-aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors. Part 2. The Impact of Bridging Groups at Position C-2. Journal of Medicinal Chemistry.(54):8517-8525.
Lee HY, Chang JY, Nien CY, Kuo CC, Shih KH, Wu CH, Chang CY, Lai WY, Liou JP*		220600331Original PaperSCI
582010Efficient microwave-assisted synthesis of ellipticine through N-(1,4-dimethyl-9H-carbazol-3-ylmethyl)-N-tosylaminoacetaldehyde diethyl acetal. J. Heterocyclic Chem..(47):454-458.
Lee, H. Y., Chen, G. S., Chen, C. S., Chern, J. W.		　1Original PaperSCI
592009An improved screening model to identify inhibitors targeting zinc-enhanced amyloid aggregation. Anal. Chem..(81):6944-6951.
Chang, P. T., Kung, F. L., Talekar, R. S., Chen, C. S., Lai, S. Y., Lee, H. Y., Chern, J. W.		22928010其他Original PaperSCI
共59筆
註：作者序1~5為第一至第五作者，C表通訊作者，E表第六作者以後或其它作者。